KOSDAQRetail & Consumer131220

Daihan Scientific

₩3,575▲ 0.14%2026-11-18 close
Market Cap
₩26.6B
Turnover
₩18,426,380
Volume
5.2K
Shares out.
7.5M
PER
6.6×
PBR
0.5×
EPS
₩535
Dividend Yield
3.55%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩125 per share · Prices as of the 2026-11-18 close

01

Report overview

Profits are recovering, but margins remain below 2022 levels

Daihan Scientific's operating profit recovered in 2025 from its 2024 low and rose for three straight quarters through the third quarter of 2026, but its operating margin and profit attributable to controlling shareholders remain below 2022 levels.

  1. 1

    Sales in 2025 were KRW 81.1 billion, the largest year in 2022 to 2025, up 13.1% from 2024.

  2. 2

    Operating profit bottomed at KRW 4.23 billion in 2024 and recovered to KRW 5.53 billion in 2025 (up 30.9%), but the 6.8% operating margin remains below 10.0% in 2022.

  3. 3

    Operating profit rose for three consecutive quarters, to KRW 973 million in Q1 2026, KRW 2.07 billion in Q2 and KRW 2.32 billion in Q3, after the Q4 2025 low of KRW 601 million.

  4. 4

    The debt ratio fell to 27.2% at the end of 2025 from 33.8% in 2022, and the company disclosed a corporate value-up plan in March 2026.

  5. 5

    Profit attributable to controlling shareholders totaled KRW 3.68 billion over the last four quarters, from Q4 2025 through Q3 2026.

02

Business structure

Daihan Scientific distributes and manufactures research laboratory equipment. Its business is split into laboratory equipment distribution and industrial equipment manufacturing, and according to the company profile data the sales mix is 68.26% merchandise and 31.74% products.

Distribution is a larger share than manufacturing, so a large part of sales comes from selling equipment sourced from outside. Main manufactured items have been introduced as ultra-low temperature freezers, rotary vacuum concentrators, autoclaves and heated magnetic stirrers, based on the 2019 annual report.

The company also offers products with an IoT-based system for remote control and condition monitoring. Overseas, it operates an overseas corporation and seven overseas franchise corporations and runs local-language online shopping malls alongside product and merchandise exports.

Demand comes from biopharma companies and research institutes, with expanded government R&D budgets and stronger biopharmaceutical production capacity cited as backdrop. The company disclosed a KRW 512.65 million QC analytical equipment supply contract with Daewoong Pharmaceutical Indonesia.

On competition, its combined manufacturing and distribution structure and overseas sales network are cited as strengths, while product technology and quality improvement are presented as challenges, according to its corporate value-up plan.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩21.2B₩2.3B10.9%
2025Q4₩25.2B₩600M2.4%
2026Q1₩17.6B₩1B5.5%
2026Q2₩21.6B₩2.1B9.6%
2026Q3₩21.5B₩2.3B10.8%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩72.3B₩7.2B₩4.7B10.0%12.9%33.8%
2023₩73.7B₩6.2B₩3.8B8.4%9.8%31.4%
2024₩71.7B₩4.2B₩2.7B5.9%6.4%28.3%
2025₩81.1B₩5.5B₩3.3B6.8%7.3%27.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual sales were KRW 72.3 billion in 2022, KRW 73.7 billion in 2023 (up 2.0%), KRW 71.7 billion in 2024 (down 2.7%) and KRW 81.1 billion in 2025 (up 13.1%). The largest year among 2022 to 2025 was 2025 and the smallest was 2024.

Operating profit fell from KRW 7.22 billion in 2022 to KRW 6.17 billion in 2023 (down 14.6%) and KRW 4.23 billion in 2024 (down 31.5%), then recovered to KRW 5.53 billion in 2025 (up 30.9%).

The operating margin was 10.0% in 2022, 8.4% in 2023, 5.9% in 2024 and 6.8% in 2025, so the margin remained below 2022 even as sales grew in 2025. The company attributed the increase in sales and operating profit in 2025 to recovering demand for scientific instruments.

Profit attributable to controlling shareholders was KRW 4.7 billion in 2022, KRW 3.85 billion in 2023 (down 18.2%), KRW 2.69 billion in 2024 (down 30.0%) and KRW 3.28 billion in 2025 (up 21.9%), with 2022 the largest year.

Net profit including non-controlling interests was KRW 4.78 billion in 2025, a different figure from profit attributable to controlling shareholders.

In quarterly terms, sales were KRW 21.2 billion and operating profit KRW 2.31 billion in Q3 2025, then sales rose to KRW 25.2 billion in Q4 2025 while operating profit fell to KRW 601 million (down 74.0% from the prior quarter).

Profit attributable to controlling shareholders in Q4 2025 was KRW 44.49 million, a low point. Operating profit then rose for three straight quarters, to KRW 973 million in Q1 2026, KRW 2.07 billion in Q2 and KRW 2.32 billion in Q3. Q3 2026 sales were KRW 21.5 billion, down 0.8% from the prior quarter and up 1.2% from a year earlier.

05

Industry analysis

Demand in the laboratory equipment market depends heavily on government national R&D budgets and investment in biopharmaceutical production. External commentary points to expanded government R&D budgets and stronger biopharmaceutical production capacity as drivers of equipment demand.

Growth in healthcare, biopharma and eco-friendly energy as emerging industries is also mentioned as a demand factor. The company itself attributed the 2025 increase in sales and operating profit to recovering demand for scientific instruments.

Research institute budgets can shift in timing, however, so quarterly results can swing, as in Q4 2025 when sales rose while operating profit fell sharply.

Against peers, the company combines distribution and manufacturing, and its 2019 annual report described it as a leading comprehensive laboratory equipment service company in Korea. Overseas, it is widening its merchandise export base through its overseas corporations and franchise corporations.

The operating margin fell from 10.0% in 2022 to 5.9% in 2024 before rebounding to 6.8% in 2025, so whether demand recovery carries through to margins is central to reading the industry position.

Product technology and quality competitiveness are presented as challenges, making manufacturing differentiation the reference point for future comparison.

06

Outlook

On March 27, 2026, Daihan Scientific voluntarily disclosed a corporate value-up plan, stating it aims to raise corporate value through stable sales growth and better profitability.

The plan includes strengthening manufacturing and distribution competitiveness in its laboratory and medical equipment businesses, along with technology and quality improvements. It also aims to expand global markets using overseas production and distribution bases.

The dividend payout ratio for 2025 was 28.4%, and total 2025 dividends were KRW 931.5 million, up 108.3% from KRW 447.1 million for 2024. At the March 2026 annual general meeting, the financial statements and the cash dividend proposal were approved as submitted.

On orders, the company disclosed a confirmed supply contract worth KRW 512.65 million for QC analytical equipment with Daewoong Pharmaceutical Indonesia. On results, operating profit rose for three consecutive quarters through Q3 2026, reaching KRW 2.32 billion in Q3.

The next confirmation point is whether full-year 2026 operating margin, which was 6.8% in 2025, rises further. On shareholder returns, whether the rise in total dividends carries into the dividend decision for the 2026 fiscal year is the item to confirm.

07

Valuation

PER
6.6×
PBR
0.5×
ROE
7.9%
EPS
₩535
BPS
₩6,948
Dividend per share
₩125

Valuation can be read through earnings scale and asset base. Profit attributable to controlling shareholders totaled KRW 3.68 billion over the last four quarters, so the earnings multiple sits in the single digits. The price-to-book ratio is below 1x, meaning the share price trades below book value per share.

Market capitalization is smaller than the KRW 45 billion attributable to controlling shareholders. On dividends, the 2025 payout ratio was 28.4%, and total dividends rose 108.3% from 2024.

Over time, profit attributable to controlling shareholders fell from KRW 4.7 billion in 2022 to KRW 2.69 billion in 2024 before recovering to KRW 3.28 billion in 2025, a recovery in earnings. Quarterly profit gains in 2026 are thickening the recent earnings base used for multiples.

However, the base includes volatility such as the Q4 2025 low, so reading the multiple from a single quarter can be misleading. The same facts can be read as strength from the earnings recovery and as weakness from the low margin and quarterly swings, and both readings hold at once.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Operating profit recovery and three straight quarterly gains

Operating profit recovered to KRW 5.53 billion in 2025 from a KRW 4.23 billion low in 2024. It rose for three straight quarters through Q3 2026, reaching KRW 2.32 billion. The Q3 2026 gain of 0.6% from a year earlier was modest, but the profit trend has continued.

Policy and industry backdrop for demand

Expanded government national R&D budgets and stronger biopharmaceutical production capacity are cited as factors lifting demand for lab equipment. Growth in healthcare, biopharma and eco-friendly energy industries is also mentioned. The company attributed its 2025 results gain to recovering demand for scientific instruments.

Balance sheet and expanded shareholder returns

The debt ratio fell to 27.2% at the end of 2025 from 33.8% in 2022, with total liabilities of KRW 15.4 billion. The 2025 payout ratio was 28.4%, and dividend amounts rose 108.3% from 2024. The March 2026 value-up plan includes targets for stable sales growth and better profitability.

09

Bear factors

Lower profitability than 2022

The operating margin was 10.0% in 2022 and 6.8% in 2025, a lower level. Profit attributable to controlling shareholders was KRW 4.7 billion in 2022 and KRW 3.28 billion in 2025. Sales peaked in 2025 at KRW 81.1 billion, but the margin recovery is still short of earlier levels.

Large swings in quarterly results

In Q4 2025 operating profit fell to KRW 601 million and profit attributable to controlling shareholders dropped to KRW 44.49 million. Q3 2026 sales of KRW 21.5 billion were down 0.8% from the prior quarter, so quarterly growth is uneven. Large quarterly swings make it hard to read the trend from one or two quarters.

Distribution-heavy revenue mix

According to the company profile data, merchandise accounts for 68.26% of sales versus 31.74% for products. A distribution-heavy structure can produce different margin levels from a manufacturing-heavy one. Whether sales growth translates into margin gains is the structural point to watch.

10

Risk factors

Budget and demand cycle

Demand for lab equipment depends on government R&D budgets and biotech investment cycles. Delays in budget execution or slower biotech investment could weigh on quarterly sales. Q4 2025, when sales rose but operating profit fell sharply, illustrates this volatility.

Overseas operating environment

Through overseas corporations and seven overseas franchise corporations, the company runs local shopping malls and exports, so it is exposed to local regulation and currency moves. Expanding overseas production and distribution bases may raise local operating costs and management load. Overseas sales share and profitability are not shown in figures here.

Small-cap ownership changes

As a small-cap stock, it can be sensitive to price swings and ownership shifts. Substantial shareholding reports were filed on June 30, July 21 and August 13, 2026. News alerts also reported that the CEO's stake rose by 0.12%.

11

What to watch next

  1. Fiscal year ends December 31, 2026

    A baseline for whether 2026 operating profit exceeds KRW 5.53 billion in 2025. The key question is whether Q4 2026 operating profit holds near the Q3 level of KRW 2.32 billion.

  2. Around late February 2027 (prior provisional results disclosed February 27, 2026)

    Provisional full-year 2026 sales and operating profit disclosure. Checkpoints are whether the operating margin exceeds 6.8% from 2025 and whether sales stay above KRW 81.1 billion.

  3. Around March 2027 (prior annual report filed March 19, 2026; AGM held March 27, 2026)

    The 2026 annual report will confirm final results and the cash dividend decision. It will show whether the value-up plan's sales growth and profitability targets were reflected in the figures.

  4. Timing of performance disclosure not yet set

    Progress on the KRW 512.65 million QC analytical equipment supply contract with Daewoong Pharmaceutical Indonesia. Its contribution to annual sales can be checked through supply-related disclosures.

12

Overall view

Daihan Scientific's operating profit recovered to KRW 5.53 billion in 2025 from a KRW 4.23 billion low in 2024, and it rose for three straight quarters through Q3 2026. Sales of KRW 81.1 billion in 2025 were the largest among 2022 to 2025.

However, the operating margin fell from 10.0% in 2022 to 6.8% in 2025, and Q4 2025 saw operating profit drop to KRW 601 million and profit attributable to controlling shareholders to KRW 44.49 million. On the balance sheet, the debt ratio fell to 27.2% at the end of 2025 and total dividends rose.

On valuation, the price-to-book ratio is below 1x and market capitalization is smaller than the shareholders' equity attributable to controlling shareholders. Recovery in earnings and expanded shareholder returns sit alongside a low margin and quarterly swings in the same data. The next checkpoints are full-year 2026 operating margin and final results in the 2026 annual report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. comp.fnguide.com
  2. k5.co.kr
  3. news.nate.com
  4. ssl.pstatic.net
  5. ssl.pstatic.net
  6. thinkpool.com
  7. kormedi.com
  8. news.nate.com
  9. news.nate.com
  10. edaily.co.kr
  11. wisefn.stockpoint.co.kr
  12. m.irgo.co.kr
  13. m.news.nate.com
  14. saramin.co.kr
  15. kind.krx.co.kr
  16. kind.krx.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis